- 1 Article
- 2 Evidence of a causal relationship between genetic tendency to
- 3 gain muscle mass and uterine leiomyomata
- 4 Eeva Sliz^{1,2}, Jaakko Tyrmi^{1,2}, Nilufer Rahmioglu^{6,7}, Krina T. Zondervan^{6,7}, Christian M.
- 5 Becker⁶, FinnGen, Outi Uimari^{3,4,5}*, Johannes Kettunen^{1,2}*
- 6 Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Finland
- ⁷ Biocenter Oulu, Oulu, Finland
- 8 ³ Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland
- 9 ⁴ PEDEGO Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland
- ⁵ Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu,
- 11 Finland
- 12 ⁶ Oxford Endometriosis CaRe Centre, Nuffield Department of Women's and Reproductive
- 13 Health, University of Oxford, UK
- 14 Wellcome Centre for Human Genetics, University of Oxford, UK
- *Equal contribution of the last authors
- 16 Address for correspondence:
- 17 Eeva Sliz
- 18 Center For Life Course Health Research
- 19 Faculty of Medicine
- 20 Aapistie 5A
- 21 P.O.Box 5000, 90014 University of Oulu
- 22 Oulu, Finland
- 23 phone: +358 50 305 4865
- e-mail: eeva.sliz@oulu.fi
- 25 Word count Introductory paragraph: 150
- 26 Word count Manuscript main body: 1627
- 27 Figures: 4
- 28 Tables: 1
- 29 Supplementary figures: 63
- 30 Supplementary tables: 9
- 31 References: 68
- 32 Key words: Uterine leiomyoma, GWAS, smooth muscle, muscle mass
- 33 Summary statistics will be made available through the NHGRI-EBI GWAS Catalog with
- 34 GCSTxxxxxxx upon publication.

Uterine leiomyomata (UL) are the most common benign tumours of the female genital tract with an estimated lifetime incidence of up to 70%¹. To date, 7 genome-wide association studies (GWASs) have identified 35 loci predisposing to UL. To improve the understanding of the underlying genetic pathways, we conducted the largest genetic association study of UL to date in 426,558 European women from FinnGen and a previously published UL meta-GWAS². We identified 36 novel and replicated 31 previously reported loci. Annotations of the potential candidate genes suggest involvement of smooth muscle cell (SMC) differentiation and/or proliferation-regulating genes in modulating UL risk. Our results further advocate that genetic predisposition to increased fat-free mass may be causally related to UL risk, underscoring the involvement of altered muscle tissue biology in UL pathophysiology. Overall, our findings provide novel insights into genetic risk factors related to UL, which may aid in developing novel treatment strategies.

35

36

37 38

39

40 41

42

43

44

45

46

47

58 59

60

61

62

63

64

65

66

67 68

69

70

71

72

73

74

75

76

77

78

79

80

81 82

83

48 UL are hormone-driven benign neoplasms of the uterus composed mostly of SMC and 49 fibroblasts with a profound component of extracellular matrix (ECM). UL are present in 50 single or multiple numbers, with size ranging from millimeters to 20 cm or more in diameter³. In 25-50% of women with ULs, the enlarged and deformed uterus can cause 51 symptoms such as heavy or prolonged menstrual bleeding resulting in anemia, reduced 52 fertility, and pregnancy complications⁴. Major risk factors for UL are family history, African 53 54 ancestry, increasing age up to menopause, and nulliparity⁵. Also, metabolic factors, including hypertension and increased body mass index (BMI), have been reported in association with 55 UL susceptibility⁶. Familial aggregation, twin studies, and disparity in prevalence between 56 different ethnic groups suggest that genetic factors modulate UL risk⁷⁻¹⁰. 57

Until recently, the focus in the genetics of UL has been on somatic rearrangements, and key driver variations in MED12, FH, HMGA2 and COL4A6-COL4A5 have been reported¹¹. To add understanding to the heritable genetic underpinnings, we conducted two sets of fixedeffect, inverse-variance weighted meta-analyses with data from FinnGen (18,060 cases and 105,519 female controls) and 1) a previously published UL meta-GWAS² totaling 53,534 cases and 373,024 female controls in 'META-1' and 2) the UK Biobank totaling 33,244 cases and 311,271 controls in 'META-2'. META-1 was restricted to publicly available 10,000 variants from the previous meta-GWAS², wheras the META-2 included 10,693,588 variants across the genome. In META-1, we identified 63 loci associating with UL at p<5x10⁻⁸ (Figure 1, Table S1); of these, 32 were novel (Table 1). In META-2, we identified 51 loci out of which 4 had not been associated with UL risk in prior GWASs or in META-1 (Figure 1, Table 1, Table S2). Regional association plots of the novel loci are presented in Figures S1-S36. There was no evidence of inflation in the test statistics (Figure S37). LD score (LDSC) regression-derived SNP-based heritability was estimated to be 0.099 (standard error=0.01) on the liability scale. Characterization of the genome-wide results of META-2 suggested that the key UL associated variants were mostly intronic (Figure 2A). Genes associated with UL risk (Figure 2B) were significantly enriched on pathways related to gonad development, positive regulation of growth, and cellular senescence (Figure 2C) and they were mostly expressed in uterus, cervix, and fallopian tube (Figure 2D). In two of the novel loci, we found evidence that altered gene expression mediates UL association (Figures S38-

Previous GWAS findings^{2,12-17} have indicated that genetic factors altering pathways involved in estrogen signalling, Wnt signalling, transforming growth factor (TGF)-β signalling, and cell cycle progression are associated with UL risk¹⁸. The novel loci identified in this study further underscore the involvement of pathways regulating SMC proliferation in modulation of UL risk. Many of these pathways are interrelated: for example, both estrogen and

84 progesterone increase the secretion of Wnt ligands from myometrial or leiomyoma SMC, 85 which promotes cell proliferation and tumorigenesis via activation of β -catenin¹⁹. Steroid hormones also influence the production of ECM via signalling through the TGF-β family of 86 ligands and receptors that are highly expressed in multiple fibrotic conditions 20-26 and 87 contribute to the fibrotic phenotype seen in UL^{24,25,27-29}. We identified multiple loci with 88 89 potential candidate genes functioning in one or more of these pathways, and, in the following, 90 we describe some of our key findings with the focus on loci involved in regulation of SMC 91 proliferation.

92

93

94

95

96

97 98

99

100

101

102

103 104

105

106

107 108

109

110111

112

113

114

115

116

117

118119

120 121

122 123

124 125 126

127

128

A central finding is the novel association at 17p12 harbouring myocardin (MYOCD; Figure S27). Myocardin is a transcription factor expressed in smooth muscle tissues, including most prominently arteries and colon, but also uterus (Figure S41), and it is required for SMC differentiation³⁰. The expression of myocardin has been shown to be downregulated in UL tissue compared with normal myometrium³¹. Also, it has been proposed that the loss of myocardin function may be a key factor in driving SMC proliferation in UL³¹; however, there are no reported GWAS associations implicating myocardin until now. The lead variants near MYOCD are intergenic variants with no strong evidence of altered regulatory consequences (Table S3) and, thus, a possible association-driving mechanism remains inconclusive. We identified another myocardin-related novel UL risk association near 'myocardin-induced smooth muscle cell lncRNA, inducer of differentiation' (MYOSLID), a transcriptional target of myocardin³² (Figure S6). RegulomeDB³³ annotation provided robust evidence that the association lead variant is a regulatory variant (Table S4) altering binding of multiple transcription factors (Table S5), including Fos proto-oncogene (FOS) that has been shown to be downregulated in UL³⁴. To add yet another example of a myocardin-related UL risk loci, a well-established UL risk association at 22q13.1^{2,12},16,35,36 locates near 'myocardin related transcription factor A' (MRTFA; also known as MKL1), a gene interacting with myocardin³/. Also, expression of MRTFA/MKL1 has been shown to be downregulated in UL-related deletions at $22q^{38}$.

Others have suggested that loss of myocardin function may account for the differentiation defects of human leiomyosarcoma cells during malignant transformation³⁹: downregulation of myocardin resulted in lower expression of cyclin dependent kinase inhibitor 1A (CDKN1A; also known as p21), a mediator of cell cycle G1 phase arrest, which facilitated cell cycle progression. We identified a novel UL association at 6p21.2 near CDKN1A (Figure S13); the association lead variants locate on intergenic region with possible regulatory consequences (Table S6). Previous evidence suggests that CDKN1A is among the genes, the expression of which correlates with UL size⁴⁰. Another novel UL association at 20q13.31 harbours RNA binding motif protein 38 (RBM38; Figure S29) that specifically binds to and regulates the stability of CDKN1A transcripts³⁷. In this locus, the UL risk-increasing rs13039273-C associates with lower RBM38 expression in ovary $(p=8.7\times10^{-6})$ (Table S7, Figure S42; eQTL in uterus $p=2.2\times10^{-3}$). Relevant to UL, a variant in the same locus (rs760640162) has been previously associated with 'pregnancy examination and test' $(p=5.97 \times 10^{-15})$ in the UK Biobank^{41,42}. Interestingly, estrogen receptor (ER) α has been shown to inhibit expression of myocardin³¹, suggesting that the ability of myocardin-CDKN1Asignalling to inhibit cell cycle progression may be impaired in tissues enriched with ERα. Taken together our findings and previous evidence, it seems highly probable that downregulation of myocardin-CDKN1A signalling increases the risk of UL.

- We used an automated LDSC regression pipeline⁴³ to evaluate the genetic correlations (r_g) of
- UL with other traits (Figure 2; Table S8). The most robustly correlated traits were seen for
- other gynecological traits, such as bilateral oophorectomy ($r_g=0.74$, $p=1.05\times10^{-25}$),
- hysterectomy ($r_g=0.62$, $p=3.24\times10^{-19}$), age at menarche ($r_g=-0.18$, $p=1.40\times10^{-9}$), excessive

- frequent and irregular menstruation ($r_g=0.51$, $p=5.66\times10^{-7}$), having had menopause ($r_g=-0.33$,
- $p=2.31\times10^{-5}$), and usage of hormonal replacement therapy ($r_g=0.20$, $p=5.54\times10^{-5}$). Strong
- correlations were also seen between UL and anthropometric and metabolic measures,
- including whole body fat-free mass ($r_g=0.11$, $p=4.21x10^{-5}$), high blood pressure ($r_g=0.15$,
- 137 $p=4.58 \times 10^{-6}$), and serum triglyceride level ($r_g=0.16$, $p=4.80 \times 10^{-5}$). Genetic susceptibility for
- 138 UL was also correlated with genetic susceptibility for multiple psychiatric or mood-related
- traits, including depressive symptoms ($r_g=0.20$, $p=3.31\times10^{-5}$) or neuroticism score ($r_g=0.14$,
- 140 $p=3.88 \times 10^{-5}$).
- To estimate the causal relationships between UL and the key traits showing significant r_g
- with UL, we applied two-sample Mendelian randomization. Our results suggest that genetic
- 143 tendency to accumulate fat-free mass may be causally linked to higher risk of UL
- $(p=2.37\times10^{-3})$; Figure 3; Table S9). In line with this, the higher impedance of whole body (i.e.,
- a bioelectrical measure used for estimating body composition; lower muscle mass leads to
- higher impedance) was causally associated with a lower risk of UL $(p=1.05 \times 10^{-3})$. When
- 147 considering the null causal effect of whole-body fat mass on UL risk (p=0.46), it seems
- apparent that the nominally significant $(p=8.40 \times 10^{-3})$ causal effect of BMI on UL in the
- present study and the previously reported associations of BMI with UL risk⁴⁴⁻⁴⁶ arise from the
- 150 increased lean body mass rather than fat mass. Although we did not observe horizontal
- pleiotropy, the causal estimates were heterogenic for many key traits (Table S9), suggesting
- that all the underlying genetic pathways may not function in a consistent manner thus, these
- results need to be interpreted with caution. However, in the leave-one-out sensitivity analyses
- all causal estimates were consistently positive (higher fat-free mass was causally associated
- with higher risk of UL) or negative (higher impedance was causally associated with lower
- risk of UL) suggesting that there is no single variant driving the causal associations (Figures
- 157 \$50-\$63). Regarding most of the gynecological traits, the causal direction with UL was not
- 158 clear (Table S9), suggesting that the shared molecular factors predispose to multiple
- gynecological complications simultaneously instead of one being causal to another. Of note,
- we replicated the previously reported finding of genetic predisposition to UL being causal to
- 161 excessive menstrual bleeding $(p=1.07 \times 10^{-4})$.
- The discovered causal relationship between genetic tendency to accumulate fat-free mass and
- 163 UL risk provides a novel perspective on UL-related pathophysiology. UL are considered
- 164 estrogen-dependent, and UL have higher ERα expression compared with normal uterine
- myometria^{47,48}. ERs are expressed in a variety of tissues, including all musculoskeletal
- tissues 49. In females, muscle mass and strength are closely coupled with estrogen status: girls
- begin to gain muscle mass after the onset of puberty⁵⁰ whereas in older age during
- perimenopausal and postmenopausal periods, muscle strength declines considerably^{51,52}. If
- estrogen enhances muscle growth⁵³, the observed causal relationship between fat-free mass
- and UL risk could arise secondary to high estrogen contributing to the muscle growth. Many
- of the newly identified candidate genes, however, directly regulate cell proliferation thus, it
- 172 remains possible that the estrogen-rich environment, due to sexual maturity, may trigger
- excess SMC growth resulting in ULs in women who are genetically susceptible to build up
- muscle.
- 175 Currently, the only essentially curative treatment for UL is hysterectomy, which underscores
- the high demand for the development of alternative effective therapies. Our findings double
- the number of known UL risk loci and, thus, the herein presented results provide several
- potential targets for translational research to develop pharmacologic interventions for UL.
- 179 Therapies targeted at myocardin-CDKN1A signalling or, considering the causal evidence,
- 180 other factors regulating muscle growth may hold the greatest potential.

Table 1. Novel UL risk loci.

The table reports novel distinct loci (more than 1Mb apart) containing at least one variant identified to be associated with UL at $p < 5x \cdot 10^{-8}$ in a meta-analysis of 53,534 UL cases and 373,024 female controls from FinnGen and a previously published meta-GWAS of UL² (META-1) and in a meta-analysis of 33,244 UL

cases and 311,271 female controls from FinnGen and the UK Biobank (META-2).

Locus	Chr:Pos (hg38)	Nearest gene(s)	Candidate gene(s)	rsID	EA	EAF	OR (95% CI)	P-value	HetPVal	FIN enr.
Novel loci in	Novel loci in META-1									
1q43	1:241860596	EXO1	EXO1, FH	rs4149909	G	0.03	1.13 (1.08-1.18)	1.16E-08	0.265	1.03
1q44	1:244151650	ZBTB18, C1orf100	ZBTB18, AKT3	rs2183478	G	0.18	1.07 (1.05-1.09)	1.75E-11	0.774	1.57
1q44	1:248897507	PGBD2	ZNF692	rs4335411	A	0.76	1.06 (1.04-1.08)	4.12E-10	0.376	0.98
2p14	2:66863235	MEIS1	MEIS1	rs17631680	C	0.10	0.93 (0.91-0.95)	1.93E-10	0.127	0.96
2q11.2	2:99454113	REV1	REV1	rs13392042	G	0.58	1.05 (1.03-1.06)	4.21E-11	0.217	1.21
2q33.3	2:207258660	MYOSLID, KLF7	MYOSLID	rs10804157	C	0.44	1.04 (1.03-1.05)	1.04E-08	0.143	0.87
2q37.3	2:241720139	ING5	ING5	rs34766121	T	0.24	1.06 (1.04-1.08)	5.02E-10	0.278	1.03
3p26.1	3:4674530	ITPR1	ITPR1	rs3804984	C	0.38	0.95 (0.93-0.96)	8.06E-15	0.021	1.42
3p24.2	3:24213259	THRB	THRB	rs1010961	A	0.45	1.04 (1.03-1.06)	1.64E-10	0.109	0.98
3q27.2	3:185807411	IGF2BP2	IGF2BP2	rs13060777	G	0.26	1.05 (1.04-1.07)	1.14E-11	0.595	1.10
4q23	4:99031559	METAP1	EIF4E, ADH5	rs1037475	G	0.57	1.04 (1.03-1.05)	8.38E-09	0.707	0.95
5q31.1	5:133099880	HSPA4	HSPA4	rs4367292	T	0.27	0.96 (0.94-0.97)	2.49E-08	0.882	1.15
6p21.2	6:36653670	CDKN1A	CDKN1A	rs10456443	A	0.20	0.95 (0.93-0.96)	2.67E-10	0.039	0.91
6q21	6:109054915	SESN1	SESN1	rs11153158	C	0.13	0.93 (0.92-0.95)	1.05E-10	0.243	1.19
7p14.3	7:33008785	FKBP9, NT5C3A	NT5C3A, BBS9	rs4723230	T	0.80	1.05 (1.03-1.07)	4.68E-08	0.946	1.03
7q31.31	7:121132432	CPED1	WNT16	rs12706314	A	0.53	1.04 (1.03-1.06)	2.69E-10	0.777	0.89
7q32.3	7:130935964	LINC-PINT	LINC-PINT	rs35908158	C	0.08	1.08 (1.05-1.10)	1.60E-08	0.883	1.41
8p12	8:30452819	RBPMS	RBPMS	rs13275869	C	0.49	0.96 (0.95-0.97)	8.64E-09	0.520	0.98
8q24.21	8:128506035	LINC00824	LINC00824	rs1516980	C	0.25	0.96 (0.94-0.97)	2.72E-08	0.987	0.76
9q22.2	9:89639982	GADD45G	GADD45G	rs28508285	G	0.09	1.07 (1.04-1.09)	1.49E-08	0.362	1.05
10p12.31	10:21517903	SKIDA1	DNAJC1	rs946711	C	0.33	1.05 (1.03-1.06)	2.96E-10	0.460	0.96
10q23.31	10:88331783	RNLS	RNLS	rs1426619	T	0.45	1.04 (1.03-1.06)	4.92E-09	0.653	1.09
11q23.2	11:112703765	LOC1053694962	LOC105369496	rs10891420	C	0.42	1.05 (1.03-1.06)	1.38E-10	0.019	1.16
15q23	15:67922458	SKOR1	PIAS1	rs12148374	C	0.44	0.96 (0.95-0.97)	1.37E-09	0.832	1.10
16q12.1	16:50059327	HEATR3	BRD7	rs12599260	A	0.73	1.05 (1.04-1.07)	1.09E-11	0.002	1.08
16q12.1	16:51447685	AC007344.1	AC007344.1	rs66998222	A	0.19	0.94 (0.93-0.96)	7.53E-12	0.345	0.79
17p12	17:12652500	MYOCD	MYOCD	rs12601765	T	0.30	1.04 (1.03-1.06)	3.08E-08	0.400	1.17
19p12	19:22032639	ZNF257	ZNF257	rs8105767	G	0.30	1.05 (1.03-1.06)	2.63E-09	0.143	1.15
20q13.31	20:57441016	CTCFL	RBM38, BMP7	rs13039273	C	0.46	1.04 (1.03-1.06)	3.08E-09	0.874	1.22
20q13.33	20:63638397	STMN3	SLC2A4RG	rs75691080	T	0.10	0.92 (0.90-0.95)	7.79E-11	0.044	1.25
21q22.12	21:35072824	RUNX1	RUNX1	rs2834747	G	0.30	0.96 (0.94-0.97)	1.44E-08	0.711	1.17
22q12.3	22:36287509	MYH9, APOL1	MYH9	rs9610482	T	0.19	1.06 (1.04-1.08)	7.89E-11	0.354	0.94
Novel loci in META-2										
2p11.2	2:86458018	KDM3A	KDM3A	rs573520030	T	0.99	0.62 (0.53-0.74)	3,87E-08	0.918	1.83
4p11	4:49085558	CWH43	OCIAD1	rs538533131	A	0.99	0.53 (0.43-0.65)	2,61E-09	0.002	1.15
10q25.1	10:106821670	SORCS1	SORCS1	rs12247648	T	0.03	1.26 (1.17-1.36)	3,86E-09	0.825	39.55
Xp11.23	X:46904059	JADE3,RP2	SLC9A7	rs6611312	T	0.53	1.05 (1.03-1.07)	2,54E-08	0.355	1.07

Chr, chromosome; Pos, position (build 38); EA, effect allele; EAF, effect allele frequency; OR, odds ratio; CI, confidence interval; P, p-value; HetPVal, p-value for heterogeneity; FIN enr, Finnish enrichment (calculated as FIN AF / NFEE AF in the Genome Aggregation Database (gnomAD), where FIN AF is the Finnish allele frequency and NFEE AF is the non-Finnish-non-Estonian European allele frequency). 'Nearest gene(s)' reports the gene closest to the association lead variant. 'Candidate gene(s)' indicates the biologically most relevant gene within 1Mb window around the association lead variant.

Figure 1. A combined Manhattan plot of UL associations in META-1 and META-2.

We conducted UL GWAS in FinnGen and, subsequently, two sets of meta-analyses with data from a previously published UL meta-analysis² and the UK Biobank, adding up to 53,534 UL cases and 373,024 female controls in META-1 (top) and 33,244 UL cases and 311,271 female controls in META-2 (bottom), respectively. Blue color denotes novel UL risk loci identified in META-1, and red color indicates novel loci identified in META-2 that were not associated previously with UL risk in prior GWASs or META-1. Black and grey colours indicate odd and even chromosome numbers, respectively. The red dashed lines correspond to the threshold for genome-wide significance (p<5x10⁻⁸).




Figure 2. Variant summary and gene set-based results using summary statistics from META-2.

A) The proportions of 'independent genome-wide significant variants' and 'variants in LD with independent significant variants' having corresponding functional annotation. Bars are colored according to $-\log_2(\text{enrichment})$ relative to all variants in the reference panel. B) A Manhattan plot of the gene-based test computed by MAGMA⁵⁴. The input variants were mapped to 19,920 protein coding genes and, thus, significance was considered at $p < 2.51 \times 10^{-6}$ (0.05/19,920); only 87 genes with p-values below this threshold are plotted. Blue and red colours indicate odd and even chromosome numbers, respectively. C) MAGMA⁵⁴ gene-set enrichment analysis was performed for curated gene sets and GO terms available at MsigDB⁵⁵. The plot shows the results for significantly enriched pathways ($p_{\text{Bonferroni}} < 0.05$). D) Results of MAGMA⁵⁴ tissue expression analysis testing a positive relationship between tissue-specific gene expression profiles and disease-gene associations. Tissue-specific gene-expression data were from GTEx (v8)⁵⁶. All data plotted in Figure 2 A-D were produced




Figure 3. Genetic correlations (r_g) of UL with other traits.

The analyses were completed using an automated LD score regression pipeline available at http://ldsc.broadinstitute.org/43. Statistical significance was considered at $p < 6 \times 10^{-5}$ (0.05/830, where 830 is the number of traits tested). The results of traits that showed significant r_g with UL are plotted (more results are provided in Table S8). Traits are named as reported in the LD Hub output.





Figure 4. Causal relationships between UL and body composition measures.

We estimated causal relationships between UL and the key traits showing significant genetic correlation with UL using two-sample Mendelian randomization implemented in 'TwoSampleMR' R library^{58,59}. Bi-directional causal estimates were obtained by using summary statistics provided by the MRC Integrative Epidemiology Unit (IEU) GWAS database and UL GWAS results obtained in FinnGen in the present study to extract genetic instruments for other, mostly UKBB-based, traits and UL, respectively. LD pruning was completed using European population reference, threshold of r²=0.001, and clumping window of 10kb. Statistical significance was considered at $p < 3 \times 10^{-3}$ (0.05/19, where 19 is the number of traits tested; black diamonds). The plot shows the causal estimates obtained using inverse variance weighted method for key body composition measures (more results are provided in Table S9; the scatter plots for the body composition measures can be found in Figures S43-S49, and the results of the leave-one-out sensitivity analyses are showin in Figures S50-S Al Exposure to LM



Methods

234

- 235 Study populations
- FinnGen (www.finngen.fi/en) is a public-private partnership project launched in 2017 with
- an aim to improve human health through genetic research. The project utilizes genome
- 238 information from a nationwide network of Finnish biobanks that are linked with digital health
- records from national hospital discharge (available from 1968), death (1969-), cancer (1953-
- 240), and medication reimbursement (1995-) registries using the unique national personal
- 241 identification codes. Ultimately, the data resource will cover roughly 10% of the Finnish
- population. We studied data from 123,579 female participants (18,060 UL cases and 105,519
- 243 female controls) from FinnGen Preparatory Phase Data Freeze 5. UL cases were required to
- have an entry of ICD-10: D25, ICD-9: 218, or ICD-8: 21899, and participants who had no
- records of these entries were deemed as controls. The Coordinating Ethics Committee of the
- 246 Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr
- 247 HUS/990/2017.
- 248 The FinnGen study is approved by Finnish Institute for Health and Welfare (THL), approval
- 249 number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017,
- 250 THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019,
- 251 THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017-3,
- 252 VRK/6909/2018-3, VRK/4415/2019-3 the Social Insurance Institution (KELA) KELA
- 253 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, and Statistics
- 254 Finland TK-53-1041-17.
- 255 The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data
- 256 Freeze 5 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34,
- 257 BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, Finnish Red Cross Blood
- 258 Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154,
- 259 Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018,
- 260 Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and
- 261 Terveystalo Biobank STB 2018001.
- FibroGENE is consortium of conventional, population-based and direct-to-consumer cohorts
- that was assembled to replicate and identify UL risk variants. In the study by Gallagher et al.,
- they studied data from 35,474 UL cases and 267,505 female controls including participants
- from four population-based cohorts (Women's Genome Health Study, WGHS; Northern
- 266 Finland Birth Cohort, NFBC; QIMR Berghofer Medical Research Institute, QIMR; the UK
- 267 Biobank, UKBB) and one direct-to-consumer cohort (23andMe) Detailed descriptions of
- 268 cohorts and sample selections are available in Supplementary Methods².
- 269 The UK Biobank is a large national and international health resource following the health
- and wellbeing of 500,000 male and female volunteer participants, enrolled at ages from 40 to
- 271 69 60. The study began in 2006 with the aim to follow the participants for at least 30 years
- 272 thereafter. Information has been collected from participants during recruitment using
- 273 questionnaires on socioeconomic status, lifestyle, family history and medical history.
- 274 Participants have also been followed up for cause-specific morbidity and mortality through
- 275 linkage to disease registries, death registries, and hospital admission records. For this study,
- altogether 220,936 women of European ancestry were considered. Based on both hospital-
- 277 linked medical records and self-report (interview with research nurse), women with a history
- of UL were selected as cases (n=15,184), while controls (n=205,752) had no previous history
- of UL. Informed consent was obtained from all participants. The UKBB project is approved
- by the North West Multi-Centre Research Ethics Committee.

- 281 Genotyping, imputation, and quality control
- 282 In FinnGen, genotyping of the samples was performed using Illumina and Affymetrix arrays
- 283 (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA). Sample
- quality control (QC) was performed to exclude individuals with high genotype missingness
- 285 (>5%), ambiguous gender, excess heterozygosity (±4SD) and non-Finnish ancestry.
- 286 Regarding variant QC, all variants with low Hardy-Weinberg equilibrium (HWE) p-value
- 287 (<1e-6), high missingness (>2%) and minor allele count (MAC)<3 were excluded. Chip
- 288 genotyped samples were pre-phased with Eagle 2.3.5 with the number of conditioning
- 289 haplotypes set to 20,000. Genotype imputation was carried out by using the Finnish
- 290 population-specific SISu v3 reference panel with Beagle 4.1 (version 08Jun17.d8b) as
- described in the following protocol: dx.doi.org/10.17504/protocols.io.nmndc5e. In post-
- imputation QC, variants with imputation INFO<0.6 were excluded.
- 293 In UK Biobank, genotyping of samples was performed either on the Affymetrix UK BiLEVE
- 294 or Affymetrix UK Biobank Axiom array. The UK Biobank genotype data passed centralised
- 295 quality control and was imputed by the UKBB team up to the HRC reference panel⁶¹.
- 296 GWAS
- 297 The UL GWAS in FinnGen was completed using the Scalable and Accurate Implementation
- of Generalized (SAIGE) software⁶². The association models were adjusted for age, sex, the
- 299 first 10 genetic principal components, and genotyping batch, and only variants with minimum
- allele count of 5 were included in the analysis.
- 301 Given the extensive relatedness in the UK Biobank data, a linear mixed model (LMM) was
- 302 utilised for association testing that accounts for population structure and model the related
- individuals, including genotyping array, age and BMI as covariates as implemented in Bolt-
- 304 LMM V2.3.
- 305 Meta-analyses
- 306 Two sets of fixed-effect, inverse-variance weighted meta-analyses (implemented in
- METAL⁶³) were performed: the results obtained in FinnGen were meta-analyzed with 1) the
- top 10,000 most significant variants associating with UL in a published GWAS² (META-1)
- and 2) UL GWAS results obtained in the UKBB. Statistical significance was considered at
- 310 the standard genome-wide significance level ($p < 5 \times 10^{-8}$). Genomic inflation factor was
- estimated using an automated LD score (LDSC) regression pipeline⁴³.
- 312 Characterization of association signals
- 313 We used a web-based platform FUMA⁵⁷ to perform functional annotations of the GWAS
- 314 results: we completed functional gene mapping and gene-based association and enrichment
- 315 tests using the genome-wide UL associations from META-2 (FinnGen and UKBB) and
- 316 predefined lead variants as reported in Table S2. FUMA identifies variants showing genome-
- 317 wide significant association ($p < 5 \times 10^{-8}$) with the study trait and, among the significant
- variants, identifies variants in low LD (r²<0.6) as 'independent significant variants' and
- 319 further identifies variants in LD (r²>0.6) with the 'independent significant variants';
- intuitier definities variants in LD (1/0.0) with the independent significant variants,
- ANNOVAR⁶⁴ annotations are performed for all these variants to obtain information on the functional consequences of the key variants. MAGMA⁵⁴, also implemented in FUMA, was
- functional consequences of the key variants. MAGMA⁵⁴, also implemented in FUMA, was used to perform gene-based association testing and gene-set enrichment analyses: gene-based
- 323 p-values were computed for protein-coding genes by mapping variants to genes and
- 324 subsequent enrichment analyses were performed for the significant genes using 4728 curated
- gene sets and 6166 GO terms as reported in MsigDB⁵⁵.

- 326 To further characterize the potential UL candidate gene(s) according to biological relevance,
- we annotated all genes within ±1Mb window from the association lead variant. We explored
- 328 information provided by GenBank³⁷ and UniProt⁶⁵ to determine functions of the genes. To
- 329 complement the information available in these databases, a broad literature search was
- performed to identify previous work published regarding to the genes of interest.
- In each locus, we explored the associations of the lead variant with gene expression levels in
- the Genotype-Tissue Expression (GTEx) Portal; GTEx was accessed during 02/10/2021-
- 333 02/11/2021. To further test if altered gene expression mediates UL risk associations, we used
- a method proposed by Zhu et al. 66 as implemented in Complex Traits Genetics Virtual Lab
- 335 (CTG-VL)⁶⁷; we performed these tests using genome-wide UL results from META-2 and
- tissue-specific gene expression data (GTEx, V7) for uterus and whole blood. We further used
- RegulomeDB³³ to discover regulatory elements overlapping with the intergenic variants in
- 338 the novel loci showing genome-wide significant association with UL risk. Here, significant
- results for the novel loci are reported.
- 340 SNP-based heritability and genetic correlations
- 341 The SNP-based heritability (h²_{SNP}) of UL was estimated using LDSC regression implemented
- in LDSC software⁶⁸. Population prevalence of 0.30 (as in ²) and sample prevalence of 0.11
- were used to estimate h²_{SNP} on liability scale. We further applied LDSC to estimate genetic
- 344 correlation (r_g) of UL with other traits using LD Hub⁴³, a web interface for performing
- 345 automated LDSC regression. As recommended, we excluded the major histocompatilibity
- complex region from the analyses⁴³. We tested r_g between UL and all 830 traits available in
- 347 the LD Hub database and, thus, statistical significance was considered at $p < 6 \times 10^{-5}$
- 348 (0.05/830).
- 349 Mendelian randomization
- To test for causal inferences between UL and the key traits showing significant r_g with UL,
- 351 we performed bi-directional two-sample Mendelian randomization. These analyses were
- 352 completed using 'TwoSampleMR' R library⁵⁸ (https://mrcieu.github.io/TwoSampleMR/). To
- avoid possible bias from overlapping samples, we extracted genetic instruments for UL from
- 354 the GWAS results obtained in FinnGen, and for other traits from the GWAS database
- 355 provided by the MRC Integrative Epidemiology Unit (IEU) available at
- 356 https://gwas.mrcieu.ac.uk/ and integrated in TwoSampleMR. LD pruning was completed
- using European population reference, threshold of r^2 =0.001, and clumping window of 10kb,
- as set as default in 'clump_data' function; the numbers of SNPs available for the analyses are
- 359 listed in Table S9. Inverse variance weighted (IVW) method was considered as a primary
- analysis, and MR Egger estimates were derived in sensitivity analyses: the estimates were
- 361 required to be to a matching direction with the IVW-estimates and Egger intercepts were
- 362 evaluated to assess horizontal pleiotropy. Cochran's Q statistics were derived using
- 363 'mr_heterogeneity' function to test for heterogeneity. To screen for highly influential variants
- that could drive the association for example due to horizontal pleiotropy, we performed
- 365 leave-one-out analyses using 'mr_leaveoneout' function. Statistical significance for the
- causal effects was considered at $p < 3 \times 10^{-3}$ (0.05/19) to correct for 19 traits tested.

Acknowledgements and funding

367

- 368 The work was supported through The Sigrid Juselius Foundation (JK) and funds from the
- 369 Academy of Finland [grant numbers 297338 and 307247](JK), Novo Nordisk Foundation
- [grant number NNF17OC0026062] (JK), and The Finnish Medical Association (OU).
- 371 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and
- 372 UH 4386/31/2016) and eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen
- 373 MA Inc, Celgene Corporation, Celgene International II Sàrl, Genentech Inc, Merck Sharp &
- 374 Dohme Corp, Pfizer Inc., GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech
- 375 Inc). Following biobanks are acknowledged for delivering biobank samples to Finngen:
- 376 Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki
- 377 Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland
- 378 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-
- 379 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-
- 380 <u>US/Research and development/Finnish Clinical Biobank Tampere</u>), Biobank of Eastern
- 381 Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-
- 382 <u>FI/Potilaalle/Biopankki</u>), Finnish Red Cross Blood Service Biobank
- 383 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank
- 384 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish
- 385 Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi).
- 386 This research has been conducted using data from UK Biobank, a major biomedical database,
- 387 (http://www.ukbiobank.ac.uk/) under project ID 9637 (Gallagher et al., 2019).
- 388 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the
- 389 Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI,
- 390 NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were
- 391 obtained from the GTEx Portal on 02/10/2021-02/11/2021.

392 Author contributions

- 393 OU conceptualized the study. ES, NR, KTZ, CMB, and JK contributed to the analysis plan.
- 394 ES, JT and NR analyzed data and generated results. ES, JT, NR, KTZ, and OU interpreted
- 395 the results. ES and OU wrote the original manuscript. JK supervised the study, obtained
- 396 funding and provided additional study resources. All authors contributed to revising the
- 397 content of the manuscript and approved the final version.

398 Competing interests

- 399 KTZ: Competing financial interests: Scientific collaborations (grant funding) with Bayer AG,
- 400 Roche Diagnostics Inc, MDNA Life Sciences, and Evotec. Competing non-financial
- 401 interests: Board memberships of the World Endometriosis Society, World Endometriosis
- 402 Research Foundation, and research advisory committee member of Wellbeing of Women
- 403 UK.
- 404 CMB: Competing financial interests: Scientific collaborations (grant funding) with Bayer
- 405 AG, Roche Diagnostics Inc, MDNA Life Sciences, and Evotec. Scientific board Myovant;
- 406 IDDM Member ObsEva. Competing non-financial interests: Chair ESHRE Endometriosis
- 407 Guideline Development Group.

References

408

- 409 1 Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D. & Schectman, J. M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. *Am. J. Obstat. Gynacol.* **188**, 100, 107 (2003)
- 411 Obstet. Gynecol. 188, 100-107 (2003).
- 412 2 Gallagher, C. S. *et al.* Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. *Nat Commun* **10**, 4857, doi:10.1038/s41467-019-12536-4 (2019).
- 415 3 Abdul Ghaffar, N. A., Ismail, M. P., Nik Mahmood, N. M., Daud, K. & Abu Dzarr, G. A. Huge uterine fibroid in a postmenopausal woman associated with polycythaemia: a case report. *Maturitas* **60**, 177-179, doi:10.1016/j.maturitas.2008.03.013 (2008).
- 418 4 Stewart, E. A. *et al.* Uterine fibroids. *Nat Rev Dis Primers* **2**, 16043, 419 doi:10.1038/nrdp.2016.43 (2016).
- 420 5 Stewart, E. A., Cookson, C. L., Gandolfo, R. A. & Schulze-Rath, R. Epidemiology of uterine fibroids: a systematic review. *BJOG* **124**, 1501-1512, doi:10.1111/1471-0528.14640 (2017).
- 422 6 Pavone, D., Clemenza, S., Sorbi, F., Fambrini, M. & Petraglia, F. Epidemiology and Risk 423 Factors of Uterine Fibroids. *Best Pract. Res. Clin. Obstet. Gynaecol.* **46**, 3-11, 424 doi:10.1016/j.bpobgyn.2017.09.004 (2018).
- Van Voorhis, B. J., Romitti, P. A. & Jones, M. P. Family history as a risk factor for development of uterine leiomyomas. Results of a pilot study. *J. Reprod. Med.* **47**, 663-669 (2002).
- 428 8 Luoto, R. *et al.* Heritability and risk factors of uterine fibroids--the Finnish Twin Cohort study. *Maturitas* **37**, 15-26 (2000).
- Treloar, S. A., Martin, N. G., Dennerstein, L., Raphael, B. & Heath, A. C. Pathways to hysterectomy: insights from longitudinal twin research. *Am. J. Obstet. Gynecol.* **167**, 82-88, doi:10.1016/s0002-9378(11)91632-9 (1992).
- 433 10 Wise, L. A. *et al.* African ancestry and genetic risk for uterine leiomyomata. *Am. J. Epidemiol.* **176**, 1159-1168, doi:10.1093/aje/kws276 (2012).
- Mehine, M., Makinen, N., Heinonen, H. R., Aaltonen, L. A. & Vahteristo, P. Genomics of uterine leiomyomas: insights from high-throughput sequencing. *Fertil. Steril.* **102**, 621-629, doi:10.1016/j.fertnstert.2014.06.050 (2014).
- Cha, P. C. *et al.* A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. *Nat. Genet.* **43**, 447-450, doi:10.1038/ng.805 (2011).
- Eggert, S. L. *et al.* Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata. *Am. J. Hum. Genet.* **91**, 621-628, doi:10.1016/j.ajhg.2012.08.009 (2012).
- Hellwege, J. N. *et al.* A multi-stage genome-wide association study of uterine fibroids in African Americans. *Hum. Genet.* **136**, 1363-1373, doi:10.1007/s00439-017-1836-1 (2017).
- Valimaki, N. *et al.* Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability. *Elife* **7**, doi:10.7554/eLife.37110 (2018).
- Rafnar, T. *et al.* Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits. *Nat Commun* **9**, 3636, doi:10.1038/s41467-018-05428-6 (2018).
- 450 17 Sakai, K. *et al.* Identification of a novel uterine leiomyoma GWAS locus in a Japanese population. *Sci. Rep.* **10**, 1197, doi:10.1038/s41598-020-58066-8 (2020).
- 452 18 Sepulveda, P. V., Bush, E. D. & Baar, K. Pharmacology of manipulating lean body mass. 453 *Clin. Exp. Pharmacol. Physiol.* **42**, 1-13, doi:10.1111/1440-1681.12320 (2015).

- Ono, M. *et al.* Paracrine activation of WNT/beta-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 17053-17058, doi:10.1073/pnas.1313650110 (2013).
- 457 20 Willert, K. & Nusse, R. Wnt proteins. *Cold Spring Harb. Perspect. Biol.* **4**, a007864, doi:10.1101/cshperspect.a007864 (2012).
- Borahay, M. A. *et al.* Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications. *Reprod. Sci.* **24**, 1235-1244, doi:10.1177/1933719116678686 (2017).
- 462 22 Massaad-Massade, L. *et al.* HMGA1 enhances the transcriptional activity and binding of the estrogen receptor to its responsive element. *Biochemistry* **41**, 2760-2768, doi:10.1021/bi011455j (2002).
- Dhamad, A. E., Zhou, Z., Zhou, J. & Du, Y. Systematic Proteomic Identification of the Heat Shock Proteins (Hsp) that Interact with Estrogen Receptor Alpha (ERalpha) and Biochemical Characterization of the ERalpha-Hsp70 Interaction. *PLoS One* 11, e0160312, doi:10.1371/journal.pone.0160312 (2016).
- 469 24 Prossnitz, E. R. *et al.* Estrogen signaling through the transmembrane G protein-coupled 470 receptor GPR30. *Annu. Rev. Physiol.* **70**, 165-190, 471 doi:10.1146/annurev.physiol.70.113006.100518 (2008).
- Ciarmela, P. *et al.* Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. *Hum. Reprod. Update* **17**, 772-790, doi:10.1093/humupd/dmr031 (2011).
- 475 26 Peng, L. *et al.* Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. *Fertil. Steril.* **91**, 2664-2675, doi:10.1016/j.fertnstert.2007.10.083 (2009).
- 478 27 Perrot, V. & Rechler, M. M. The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. *Mol. Endocrinol.* **19**, 480 2283-2298, doi:10.1210/me.2004-0292 (2005).
- Guo, S. *et al.* Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. *J. Biol. Chem.* **274**, 17184-17192, doi:10.1074/jbc.274.24.17184 (1999).
- Lewis, T. D. *et al.* Ulipristal acetate decreases active TGF-beta3 and its canonical signaling in uterine leiomyoma via two novel mechanisms. *Fertil. Steril.* **111**, 806-815 e801, doi:10.1016/j.fertnstert.2018.12.026 (2019).
- 488 30 Chen, J., Kitchen, C. M., Streb, J. W. & Miano, J. M. Myocardin: a component of a molecular switch for smooth muscle differentiation. *J. Mol. Cell. Cardiol.* **34**, 1345-1356, doi:10.1006/jmcc.2002.2086 (2002).
- 491 31 Liao, X. H. *et al.* ERalpha inhibited myocardin-induced differentiation in uterine fibroids. 492 *Exp. Cell Res.* **350**, 73-82, doi:10.1016/j.yexcr.2016.11.007 (2017).
- Zhao, J. et al. MYOSLID Is a Novel Serum Response Factor-Dependent Long Noncoding
 RNA That Amplifies the Vascular Smooth Muscle Differentiation Program. Arterioscler.
 Thromb. Vasc. Biol. 36, 2088-2099, doi:10.1161/ATVBAHA.116.307879 (2016).
- Boyle, A. P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* **22**, 1790-1797, doi:10.1101/gr.137323.112 (2012).
- 498 34 Raimundo, N., Vanharanta, S., Aaltonen, L. A., Hovatta, I. & Suomalainen, A. Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. *Oncogene* **28**, 1261-1273, doi:10.1038/onc.2008.472 (2009).

501	35	Edwards, T. L., Hartmann, K. E. & Velez Edwards, D. R. Variants in BET1L and TNRC6B
502		associate with increasing fibroid volume and fibroid type among European Americans. Hum.
503		Genet. 132, 1361-1369, doi:10.1007/s00439-013-1340-1 (2013).

- 504 36 Masuda, T. *et al.* GWAS of five gynecologic diseases and cross-trait analysis in Japanese. 505 *Eur. J. Hum. Genet.* **28**, 95-107, doi:10.1038/s41431-019-0495-1 (2020).
- 506 37 Clark, K., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J. & Sayers, E. W. GenBank. *Nucleic Acids Res.* **44**, D67-72, doi:10.1093/nar/gkv1276 (2016).
- 508 38 Mehine, M. *et al.* Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. *Proc. Natl. Acad. Sci. U. S. A.* 113, 1315-1320, doi:10.1073/pnas.1518752113 (2016).
- 511 39 Kimura, Y., Morita, T., Hayashi, K., Miki, T. & Sobue, K. Myocardin functions as an effective inducer of growth arrest and differentiation in human uterine leiomyosarcoma cells. *Cancer Res.* **70**, 501-511, doi:10.1158/0008-5472.CAN-09-1469 (2010).
- Markowski, D. N. *et al.* HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas. *Genes Chromosomes Cancer* **49**, 661-668, doi:10.1002/gcc.20777 (2010).
- 517 41 Staley, J. R. *et al.* PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics* **32**, 3207-3209, doi:10.1093/bioinformatics/btw373 (2016).
- 519 42 Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human genotype-520 phenotype associations. *Bioinformatics* **35**, 4851-4853, doi:10.1093/bioinformatics/btz469 521 (2019).
- Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* 33, 272-279, doi:10.1093/bioinformatics/btw613 (2017).
- Marshall, L. M. *et al.* Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. *Epidemiology* **9**, 511-517 (1998).
- Wise, L. A. *et al.* Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. *Epidemiology* **16**, 346-354 (2005).
- 530 46 Lee, J. E. *et al.* Weight change and risk of uterine leiomyomas: Korea Nurses' Health Study. 531 *Curr. Med. Res. Opin.* **34**, 1913-1919, doi:10.1080/03007995.2018.1462783 (2018).
- Bakas, P. *et al.* Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. *Fertil. Steril.* **90**, 1878-1885, doi:10.1016/j.fertnstert.2007.09.019 (2008).
- Valladares, F. *et al.* Characterization of estrogen receptors alpha and beta in uterine leiomyoma cells. *Fertil. Steril.* **86**, 1736-1743, doi:10.1016/j.fertnstert.2006.05.047 (2006).
- 537 49 Sipila, S. & Poutamo, J. Muscle performance, sex hormones and training in peri-menopausal 538 and post-menopausal women. *Scand. J. Med. Sci. Sports* **13**, 19-25, doi:10.1034/j.1600-0838.2003.20210.x (2003).
- Wood, C. L., Lane, L. C. & Cheetham, T. Puberty: Normal physiology (brief overview). *Best Pract. Res. Clin. Endocrinol. Metab.* **33**, 101265, doi:10.1016/j.beem.2019.03.001 (2019).
- 542 51 Barros, R. P. & Gustafsson, J. A. Estrogen receptors and the metabolic network. *Cell Metab* **14**, 289-299, doi:10.1016/j.cmet.2011.08.005 (2011).
- 544 52 Chidi-Ogbolu, N. & Baar, K. Effect of Estrogen on Musculoskeletal Performance and Injury Risk. *Front. Physiol.* **9**, 1834, doi:10.3389/fphys.2018.01834 (2018).

546	53	Velders, M. & Diel, P. How sex hormones promote skeletal muscle regeneration. Sports Med.
547		43 , 1089-1100, doi:10.1007/s40279-013-0081-6 (2013).

- 548 54 de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set 549 analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219, 550 doi:10.1371/journal.pcbi.1004219 (2015).
- 551 55 Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739-1740, doi:10.1093/bioinformatics/btr260 (2011).
- 553 56 Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580-585, doi:10.1038/ng.2653 (2013).
- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826, doi:10.1038/s41467-017-01261-5 (2017).
- Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**, doi:10.7554/eLife.34408 (2018).
- Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS genetics* **13**, e1007081, doi:10.1371/journal.pgen.1007081 (2017).
- 563 60 Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779, doi:10.1371/journal.pmed.1001779 (2015).
- 566 61 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 567 562, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335-1341, doi:10.1038/s41588-018-0184-y (2018).
- Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191, doi:10.1093/bioinformatics/btq340 (2010).
- Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164, doi:10.1093/nar/gkq603 (2010).
- 577 65 UniProt, C. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* 47, D506-D515, doi:10.1093/nar/gky1049 (2019).
- Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481-487, doi:10.1038/ng.3538 (2016).
- Cuéllar-Partida, G. *et al.* Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses. *bioRxiv*, 518027, doi:10.1101/518027 (2019).
- Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291-295, doi:10.1038/ng.3211 (2015).

585 586

Contributors of FinnGen

588 **Steering Committee** 589 590

587

591

614

615

637

641

642

Aarno Palotie Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Mark Daly Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Pharmaceutical companies

592 593 Bridget Riley-Gills Abbvie, Chicago, IL, United States 594 Howard Jacob Abbvie, Chicago, IL, United States 595 Astra Zeneca, Cambridge, United Kingdom Dirk Paul 596 Heiko Runz Biogen, Cambridge, MA, United States 597 Sally John Biogen, Cambridge, MA, United States

598 Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States Robert Plenge 599 Joseph Maranville Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States

600 Mark McCarthy Genentech, San Francisco, CA, United States Genentech, San Francisco, CA, United States 601 Julie Hunkapiller 602 Meg Ehm GlaxoSmithKline, Brentford, United Kingdom 603 Kirsi Auro GlaxoSmithKline, Brentford, United Kingdom

604 Merck, Kenilworth, NJ, United States Simonne Longerich 605 Merck, Kenilworth, NJ, United States Caroline Fox 606 Anders Mälarstig Pfizer, New York, NY, United States

607 Sanofi, Paris, France Katherine Klinger 608 Deepak Raipal Sanofi, Paris, France

609 Eric Green Maze Therapeutics, San Francisco, CA, United States 610 Robert Graham Maze Therapeutics, San Francisco, CA, United States

611 Robert Yang Janssen Biotech, Beerse, Belgium 612 Chris O'Donnell Novartis, Basel, Switzerland 613

University of Helsinki & Biobanks

Tomi Mäkelä HiLIFE, University of Helsinki, Finland, Finland

616 Jaakko Kaprio Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland, Finland

617 Petri Virolainen Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland 618 Antti Hakanen Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland

619 Terhi Kilpi THL Biobank / The National Institute of Health and Welfare Helsinki, Finland 620 621 622 623 624 Markus Perola THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

Jukka Partanen Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,

Helsinki, Finland Helsinki

Anne Pitkäranta Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,

625 Juhani Junttila

Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland

Raisa Serpi

Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland

626 627 628 629 630 Tarja Laitinen

Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland

631 Veli-Matti Kosma

632 633 Kuopio, Finland

Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,

Urho Kujala

Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,

634 Jyväskylä, Finland

635 636 Marco Hautalahti FINBB - Finnish biobank cooperative

Other Experts/ Non-Voting Members

638 Outi Tuovila Business Finland, Helsinki, Finland 639 Raimo Pakkanen Business Finland, Helsinki, Finland 640

Scientific Committee

Pharmaceutical companies

643 Jeffrey Waring Abbvie, Chicago, IL, United States 644 Bridget Riley-Gillis Abbvie, Chicago, IL, United States 645 Ioanna Tachmazidou Astra Zeneca, Cambridge, United Kingdom 646 Chia-Yen Chen Biogen, Cambridge, MA, United States 647 Biogen, Cambridge, MA, United States Heiko Runz

648 Shameek Biswas Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States

649 Sarah Pendergrass Genentech, San Francisco, CA, United States 650 Julie Hunkapiller Genentech, San Francisco, CA, United States 651 Meg Ehm GlaxoSmithKline, Brentford, United Kingdom 652 David Pulford GlaxoSmithKline, Brentford, United Kingdom

653 Neha Raghavan Merck, Kenilworth, NJ, United States

654	Adriana Huertas-Vazquez	Merck, Kenilworth, NJ, United States
655	Jae-Hoon Sul	Merck, Kenilworth, NJ, United States
656	Anders Mälarstig	Pfizer, New York, NY, United States
657	Xinli Hu	Pfizer, New York, NY, United States

658 Katherine Klinger Sanofi, Paris, France 659 Matthias Gossel Sanofi, Paris, France

660 Robert Graham Maze Therapeutics, San Francisco, CA, United States 661 Eric Green Maze Therapeutics, San Francisco, CA, United States 662 Sahar Mozaffari Maze Therapeutics, San Francisco, CA, United States

663 Dawn Waterworth Janssen Research & Development, LLC, Spring House, PA, United States

664 Nicole Renaud Novartis, Basel, Switzerland 665 Ma'en Obeidat Novartis, Basel, Switzerland

University of Helsinki & Biobanks

668 Samuli Ripatti Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland

669 Johanna Schleutker Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland

670 Markus Perola THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

671 Mikko Arvas Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,

672 Helsinki, Finland

666 667

689

673 Olli Carpén Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,

674 Helsinki

675 Reetta Hinttala Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital

676 District, Oulu, Finland

677 Johannes Kettunen Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital

District, Oulu, Finland

678 679 Arto Mannermaa Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,

680 Kuopio, Finland

681 Katriina Aalto-Setälä Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,

682 Tampere, Finland

683 Jari Laukkanen Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,

684 Jyväskylä, Finland

685 Urho Kujala Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,

686 Jyväskylä, Finland

687 Johanna Mäkelä FINBB - Finnish biobank cooperative 688

Clinical Groups

690 **Neurology Group**

691 Reetta Kälviäinen Northern Savo Hospital District, Kuopio, Finland 692 Valtteri Julkunen Northern Savo Hospital District, Kuopio, Finland 693 Hilkka Soininen Northern Savo Hospital District, Kuopio, Finland 694 Anne Remes Northern Ostrobothnia Hospital District, Oulu, Finland 695 Mikko Hiltunen Northern Savo Hospital District, Kuopio, Finland 696 Jukka Peltola Pirkanmaa Hospital District, Tampere, Finland

697 Minna Raivio Hospital District of Helsinki and Uusimaa, Helsinki, Finland 698 Pentti Tienari Hospital District of Helsinki and Uusimaa, Helsinki, Finland 699 Juha Rinne Hospital District of Southwest Finland, Turku, Finland 700 Roosa Kallionpää Hospital District of Southwest Finland, Turku, Finland

701 Juulia Partanen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

702 Ali Abbasi Abbvie, Chicago, IL, United States 703 Adam Ziemann Abbvie, Chicago, IL, United States 704 Jeffrey Waring Abbvie, Chicago, IL, United States 705 Sahar Esmaeeli Abbvie, Chicago, IL, United States 706 Nizar Smaoui Abbvie, Chicago, IL, United States 707 Anne Lehtonen Abbvie, Chicago, IL, United States 708 Susan Eaton Biogen, Cambridge, MA, United States 709 Biogen, Cambridge, MA, United States Heiko Runz 710 Sanni Lahdenperä Biogen, Cambridge, MA, United States

71<u>1</u> Janet van Adelsberg Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States 712 Shameek Biswas Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States

 $7\overline{13}$ Julie Hunkapiller Genentech, San Francisco, CA, United States 714 Natalie Bowers Genentech, San Francisco, CA, United States 715 Edmond Teng Genentech, San Francisco, CA, United States 716 Sarah Pendergrass Genentech, San Francisco, CA, United States Fanli Xu GlaxoSmithKline, Brentford, United Kingdom 718 GlaxoSmithKline, Brentford, United Kingdom David Pulford 719 Kirsi Auro GlaxoSmithKline, Brentford, United Kingdom 720 Laura Addis GlaxoSmithKline, Brentford, United Kingdom

721	John Eicher	GlaxoSmithKline, Brentford, United Kingdom
722	Qingqin S Li	Janssen Research & Development, LLC, Titusville, NJ 08560, United States
$7\bar{2}\bar{3}$	Karen He	Janssen Research & Development, LLC, Spring House, PA, United States
724	Ekaterina Khramtsova	Janssen Research & Development, LLC, Spring House, PA, United States
725	Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
726	Neha Raghavan	Merck, Kenilworth, NJ, United States
727	Kari Linden	Pfizer, New York, NY, United States
728 729	Control on torology Cross	
730	Gastroenterology Group Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
731	Jukka Koskela	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
732	Sampsa Pikkarainen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
733	Airi Jussila	Pirkanmaa Hospital District, Tampere, Finland
734	Katri Kaukinen	Pirkanmaa Hospital District, Tampere, Finland
735	Timo Blomster	Northern Ostrobothnia Hospital District, Oulu, Finland
736	Mikko Kiviniemi	Northern Savo Hospital District, Kuopio, Finland
737	Markku Voutilainen	Hospital District of Southwest Finland, Turku, Finland
738	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
739 740	Ali Abbasi	Abbvie, Chicago, IL, United States
740 741	Graham Heap	Abbyie, Chicago, IL, United States
742	Jeffrey Waring Nizar Smaoui	Abbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States
743	Fedik Rahimov	Abbvie, Chicago, IL, United States
744	Anne Lehtonen	Abbvie, Chicago, IL, United States
745	Keith Usiskin	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
746	Tim Lu	Genentech, San Francisco, CA, United States
747	Natalie Bowers	Genentech, San Francisco, CA, United States
748	Danny Oh	Genentech, San Francisco, CA, United States
749	Sarah Pendergrass	Genentech, San Francisco, CA, United States
750	Linda McCarthy	GlaxoSmithKline, Brentford, United Kingdom
751 752	Amy Hart	Janssen Research & Development, LLC, Spring House, PA, United States
752 753	Meijian Guan	Janssen Research & Development, LLC, Spring House, PA, United States
754	Jason Miller Kirsi Kalpala	Merck, Kenilworth, NJ, United States
755	Melissa Miller	Pfizer, New York, NY, United States Pfizer, New York, NY, United States
756	Xinli Hu	Pfizer, New York, NY, United States
757	711111 110	Tilzer, Now Tork, 111, Clinica States
758	Rheumatology Group	
759	Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
760	Antti Palomäki	Hospital District of Southwest Finland, Turku, Finland
761	Pia Isomäki	Pirkanmaa Hospital District, Tampere, Finland
762	Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland
763 764	Oili Kaipiainen-Seppänen	Northern Savo Hospital District, Kuopio, Finland
764 765	Johanna Huhtakangas	Northern Ostrobothnia Hospital District, Oulu, Finland Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland
766	Nina Mars Ali Abbasi	Abbvie, Chicago, IL, United States
767	Jeffrey Waring	Abbvie, Chicago, IL, United States
768	Fedik Rahimov	Abbvie, Chicago, IL, United States
769	Apinya Lertratanakul	Abbvie, Chicago, IL, United States
770	Nizar Smaoui	Abbvie, Chicago, IL, United States
771	Anne Lehtonen	Abbvie, Chicago, IL, United States
772	David Close	Astra Zeneca, Cambridge, United Kingdom
773	Marla Hochfeld	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
774 775	Natalie Bowers	Genentech, San Francisco, CA, United States
775 776	Sarah Pendergrass	Genentech, San Francisco, CA, United States
770 777	Jorge Esparza Gordillo Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
778	Dawn Waterworth	GlaxoSmithKline, Brentford, United Kingdom Janssen Research & Development, LLC, Spring House, PA, United States
779	Fabiana Farias	Merck, Kenilworth, NJ, United States
780	Kirsi Kalpala	Pfizer, New York, NY, United States
781	Nan Bing	Pfizer, New York, NY, United States
782	Xinli Hu	Pfizer, New York, NY, United States
783		

Pulmonology Group

Tarja Laitinen Pirkanmaa Hospital District, Tampere, Finland Margit Pelkonen Northern Savo Hospital District, Kuopio, Finland

Paula Kauppi Hospital District of Helsinki and Uusimaa, Helsinki, Finland

788	Hannu Kankaanranta	Pirkanmaa Hospital District, Tampere, Finland
789	Terttu Harju	Northern Ostrobothnia Hospital District, Oulu, Finland
790	Riitta Lahesmaa	Hospital District of Southwest Finland, Turku, Finland

Abbvie, Chicago, IL, United States Nizar Smaoui Alex Mackay Astra Zeneca, Cambridge, United Kingdom 793 Glenda Lassi Astra Zeneca, Cambridge, United Kingdom 794 Susan Eaton Biogen, Cambridge, MA, United States

Steven Greenberg Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States

796 Hubert Chen Genentech, San Francisco, CA, United States 797 Sarah Pendergrass Genentech, San Francisco, CA, United States 798 Genentech, San Francisco, CA, United States Natalie Bowers 799 Joanna Betts GlaxoSmithKline, Brentford, United Kingdom 800 Soumitra Ghosh GlaxoSmithKline, Brentford, United Kingdom 801 GlaxoSmithKline, Brentford, United Kingdom Kirsi Auro 802 Rajashree Mishra GlaxoSmithKline, Brentford, United Kingdom 803

Cardiometabolic Diseases Group

804 805 Teemu Niiranen The National Institute of Health and Welfare Helsinki, Finland 806 Felix Vaura The National Institute of Health and Welfare Helsinki, Finland 807 Veikko Salomaa The National Institute of Health and Welfare Helsinki, Finland 808 Markus Juonala Hospital District of Southwest Finland, Turku, Finland 809 Kaj Metsärinne Hospital District of Southwest Finland, Turku, Finland 810 Mika Kähönen Pirkanmaa Hospital District, Tampere, Finland Northern Ostrobothnia Hospital District, Oulu, Finland Juhani Junttila Markku Laakso Northern Savo Hospital District, Kuopio, Finland Jussi Pihlajamäki Northern Savo Hospital District, Kuopio, Finland

811 812 813 814 815 816 817 818 819 Hospital District of Helsinki and Uusimaa, Helsinki, Finland Daniel Gordin Juha Sinisalo Hospital District of Helsinki and Uusimaa, Helsinki, Finland Marja-Riitta Taskinen Hospital District of Helsinki and Uusimaa, Helsinki, Finland Tiinamaija Tuomi Hospital District of Helsinki and Uusimaa, Helsinki, Finland Jari Laukkanen Central Finland Health Care District, Jyväskylä, Finland

Amanda Elliott Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad

Institute, Cambridge, MA, United States

820 821 Joel Rämö Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 822 Samuli Ripatti Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 823 824 825 Mary Pat Reeve Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Sanni Ruotsalainen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Astra Zeneca, Cambridge, United Kingdom Benjamin Challis 826 827 Dirk Paul Astra Zeneca, Cambridge, United Kingdom

Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States Keith Usiskin

828 Julie Hunkapiller Genentech, San Francisco, CA, United States 829 Natalie Bowers Genentech, San Francisco, CA, United States 830 Sarah Pendergrass Genentech, San Francisco, CA, United States 831 Audrey Chu GlaxoSmithKline, Brentford, United Kingdom 832 Kirsi Auro GlaxoSmithKline, Brentford, United Kingdom

833 Dermot Reilly Janssen Research & Development, LLC, Boston, MA, United States

834 Jaakko Parkkinen Pfizer, New York, NY, United States 835 Melissa Miller Pfizer, New York, NY, United States 836 Russell Miller Pfizer, New York, NY, United States 837 838

Oncology Group

839 Tuomo Meretoja Hospital District of Helsinki and Uusimaa, Helsinki, Finland 840 841 Heikki Joensuu Hospital District of Helsinki and Uusimaa, Helsinki, Finland Olli Carpén Hospital District of Helsinki and Uusimaa, Helsinki, Finland 842 Hospital District of Helsinki and Uusimaa, Helsinki, Finland Lauri Aaltonen 843 Johanna Mattson Hospital District of Helsinki and Uusimaa, Helsinki, Finland 844

Annika Auranen Pirkanmaa Hospital District, Tampere, Finland 845 Peeter Karihtala Northern Ostrobothnia Hospital District, Oulu, Finland 846 847 Saila Kauppila Northern Ostrobothnia Hospital District, Oulu, Finland Päivi Auvinen Northern Savo Hospital District, Kuopio, Finland 848 Klaus Elenius Hospital District of Southwest Finland, Turku, Finland 849 Johanna Schleutker Hospital District of Southwest Finland, Turku, Finland

850 Esa Pitkänen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Nina Mars Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Mark Daly Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

853 Relia Popovic Abbvie, Chicago, IL, United States Jeffrey Waring Abbvie, Chicago, IL, United States

855	Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
856	Anne Lehtonen	Abbvie, Chicago, IL, United States

Genentech, San Francisco, CA, United States 857 Jennifer Schutzman 858 Julie Hunkapiller Genentech, San Francisco, CA, United States 859 Genentech, San Francisco, CA, United States Natalie Bowers 860 Sarah Pendergrass Genentech, San Francisco, CA, United States 861 Diptee Kulkarni GlaxoSmithKline, Brentford, United Kingdom 862 Kirsi Auro GlaxoSmithKline, Brentford, United Kingdom

863 Alessandro Porello Janssen Research & Development, LLC, Spring House, PA, United States

864 Andrey Loboda Merck, Kenilworth, NJ, United States 865 Heli Lehtonen Pfizer, New York, NY, United States 866 Stefan McDonough Pfizer, New York, NY, United States

867 Marika Crohns Sanofi, Paris, France 868 Sauli Vuoti Sanofi, Paris, France 869

Opthalmology Group

870

871 Kai Kaarniranta Northern Savo Hospital District, Kuopio, Finland

872 873 Joni A Turunen Hospital District of Helsinki and Uusimaa, Helsinki, Finland Terhi Ollila Hospital District of Helsinki and Uusimaa, Helsinki, Finland 874 875 Sanna Seitsonen Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Hannu Uusitalo Pirkanmaa Hospital District, Tampere, Finland 876 Vesa Aaltonen Hospital District of Southwest Finland, Turku, Finland 877 Hannele Uusitalo-Järvinen Pirkanmaa Hospital District, Tampere, Finland 878 879 Marja Luodonpää Northern Ostrobothnia Hospital District, Oulu, Finland Nina Hautala Northern Ostrobothnia Hospital District, Oulu, Finland

880 Juha Karjalainen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 881 Esa Pitkänen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

882 Mengzhen Liu Abbvie, Chicago, IL, United States 883 Heiko Runz Biogen, Cambridge, MA, United States 884 Stephanie Loomis Biogen, Cambridge, MA, United States 885 Erich Strauss Genentech, San Francisco, CA, United States 886 Natalie Bowers Genentech, San Francisco, CA, United States 887 Hao Chen Genentech, San Francisco, CA, United States 888 Sarah Pendergrass Genentech, San Francisco, CA, United States 889

Dermatology Group

890 891 892 Kaisa Tasanen Northern Ostrobothnia Hospital District, Oulu, Finland Laura Huilaja Northern Ostrobothnia Hospital District, Oulu, Finland 893 Katariina Hannula-Jouppi Hospital District of Helsinki and Uusimaa, Helsinki, Finland

894 Teea Salmi Pirkanmaa Hospital District, Tampere, Finland 895 Sirkku Peltonen Hospital District of Southwest Finland, Turku, Finland 896 Leena Koulu Hospital District of Southwest Finland, Turku, Finland

897 Abbvie, Chicago, IL, United States Nizar Smaoui 898 Abbvie, Chicago, IL, United States Fedik Rahimov 899 Anne Lehtonen Abbvie, Chicago, IL, United States 900 David Choy Genentech, San Francisco, CA, United States 901 Sarah Pendergrass Genentech, San Francisco, CA, United States

902 Dawn Waterworth Janssen Research & Development, LLC, Spring House, PA, United States

903 Kirsi Kalpala Pfizer, New York, NY, United States 904 Pfizer, New York, NY, United States Ying Wu 905

Odontology Group

906

921

907 Pirkko Pussinen Hospital District of Helsinki and Uusimaa, Helsinki, Finland 908 Aino Salminen Hospital District of Helsinki and Uusimaa, Helsinki, Finland 909 Tuula Salo Hospital District of Helsinki and Uusimaa, Helsinki, Finland 910 Hospital District of Helsinki and Uusimaa, Helsinki, Finland David Rice Pekka Nieminen Hospital District of Helsinki and Uusimaa, Helsinki, Finland 912 913 914 915 Ulla Palotie Hospital District of Helsinki and Uusimaa, Helsinki, Finland Juha Sinisalo Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Northern Savo Hospital District, Kuopio, Finland Maria Siponen Liisa Suominen Northern Savo Hospital District, Kuopio, Finland 916 917 Päivi Mäntylä Northern Savo Hospital District, Kuopio, Finland Hospital District of Southwest Finland, Turku, Finland Ulvi Gursoy 918 Vuokko Anttonen Northern Ostrobothnia Hospital District, Oulu, Finland 919 Northern Ostrobothnia Hospital District, Oulu, Finland Kirsi Sipilä 920

Sarah Pendergrass Genentech, San Francisco, CA, United States

Women's Health and Reproduction Group

922 923 924 Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Hannele Laivuori

Venla Kurra Pirkanmaa Hospital District, Tampere, Finland

925 Oskari Heikinheimo Hospital District of Helsinki and Uusimaa, Helsinki, Finland 926 927 Ilkka Kalliala Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Laura Kotaniemi-Talonen Pirkanmaa Hospital District, Tampere, Finland 928 929 Kari Nieminen Pirkanmaa Hospital District, Tampere, Finland Päivi Polo Hospital District of Southwest Finland, Turku, Finland 930 Kaarin Mäkikallio Hospital District of Southwest Finland, Turku, Finland 931 Eeva Ekholm Hospital District of Southwest Finland, Turku, Finland 932 933 934 Marja Vääräsmäki Northern Ostrobothnia Hospital District, Oulu, Finland Outi Uimari Northern Ostrobothnia Hospital District, Oulu, Finland Laure Morin-Papunen Northern Ostrobothnia Hospital District, Oulu, Finland 935

Northern Savo Hospital District, Kuopio, Finland Marjo Tuppurainen 936 937 Katja Kivinen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Elisabeth Widen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 938 Taru Tukiainen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 939 Mary Pat Reeve Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 940 Mark Daly Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 941 Liu Aoxing Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 942 Andrea Ganna Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

943 Eija Laakkonen University of Jyväskylä, Jyväskylä, Finland 944 Niko Välimäki University of Helsinki, Helsinki, Finland

945 Lauri Aaltonen Hospital District of Helsinki and Uusimaa, Helsinki, Finland 946 Johannes Kettunen Northern Ostrobothnia Hospital District, Oulu, Finland 947 Mikko Arvas Finnish Red Cross Blood Service, Helsinki, Finland

948 Jeffrey Waring Abbvie, Chicago, IL, United States 949 Bridget Riley-Gillis Abbvie, Chicago, IL, United States 950 Mengzhen Liu Abbvie, Chicago, IL, United States

951 Sarah Pendergrass Genentech, San Francisco, CA, United States 952 Janet Kumar GlaxoSmithKline, Brentford, United Kingdom 953 Kirsi Auro GlaxoSmithKline, Brentford, United Kingdom 954

FinnGen Analysis working group

955

956 Justin Wade Davis Abbvie, Chicago, IL, United States 957 Bridget Riley-Gillis Abbvie, Chicago, IL, United States 958 959 Abbvie, Chicago, IL, United States Reza Hammond Fedik Rahimov Abbvie, Chicago, IL, United States 960 Sabah Kadri Abbvie, Chicago, IL, United States 961 Sahar Esmaeeli Abbvie, Chicago, IL, United States 962 Abbvie, Chicago, IL, United States Mengzhen Liu 963 Slavé Petrovski Astra Zeneca, Cambridge, United Kingdom 964 Astra Zeneca, Cambridge, United Kingdom Eleonor Wigmore

965 Adele Mitchell Biogen, Cambridge, MA, United States 966 Benjamin Sun Biogen, Cambridge, MA, United States 967 Ellen Tsai Biogen, Cambridge, MA, United States 968 Denis Baird Biogen, Cambridge, MA, United States 969 Paola Bronson Biogen, Cambridge, MA, United States 970 Ruoyu Tian Biogen, Cambridge, MA, United States 971 972 Stephanie Loomis Biogen, Cambridge, MA, United States Yunfeng Huang Biogen, Cambridge, MA, United States

973 Joseph Maranville Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States 974 Shameek Biswas Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States 975 Elmutaz Mohammed Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States 976 Samir Wadhawan Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States 977 Erika Kvikstad Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States Minal Caliskan Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States

978 979 Diana Chang Genentech, San Francisco, CA, United States 980 Julie Hunkapiller Genentech, San Francisco, CA, United States 981 Tushar Bhangale Genentech, San Francisco, CA, United States 982 Natalie Bowers Genentech, San Francisco, CA, United States 983 984 Sarah Pendergrass Genentech, San Francisco, CA, United States Karen S King GlaxoSmithKline, Brentford, United Kingdom 985 Padhraig Gormley GlaxoSmithKline, Brentford, United Kingdom 986 GlaxoSmithKline, Brentford, United Kingdom Jimmy Liu

987 Karsten Sieber Janssen Research & Development, LLC, Spring House, PA, United States 988 Amy Hart Janssen Research & Development, LLC, Spring House, PA, United States

```
989
           Meijian Guan
                                       Janssen Research & Development, LLC, Spring House, PA, United States
 990
                                       Janssen Research & Development, LLC, Spring House, PA, United States
           Shicheng Guo
 991
           Beryl Cummings
                                       Maze Therapeutics, San Francisco, CA, United States
 992
           Matt Brauer
                                       Maze Therapeutics, San Francisco, CA, United States
 993
                                       Merck, Kenilworth, NJ, United States
           Jason Miller
 994
           Fabiana Farias
                                       Merck, Kenilworth, NJ, United States
 995
           Jorge Del-Aguila
                                       Merck, Kenilworth, NJ, United States
 996
           Kirill Shkura
                                       Merck, Kenilworth, NJ, United States
 997
           Victor Neduva
                                       Merck, Kenilworth, NJ, United States
 998
           Huilei Xu
                                       Novartis, Basel, Switzerland
 999
                                       Novartis, Basel, Switzerland
           Amy Cole
1000
           Jonathan Chung
                                       Novartis, Basel, Switzerland
1001
           Jaison Jacob
                                       Novartis, Basel, Switzerland
1002
           Katrina de Lange
                                       Novartis, Basel, Switzerland
1003
           Jonas Zierer
                                       Novartis, Basel, Switzerland
1004
           Xing Chen
                                       Pfizer, New York, NY, United States
1005
           Åsa Hedman
                                       Pfizer, New York, NY, United States
1006
           Clarence Wang
                                       Sanofi, Paris, France
1007
           Ethan Xu
                                       Sanofi, Paris, France
1008
           Franck Auge
                                       Sanofi, Paris, France
1009
           Clement Chatelain
                                       Sanofi, Paris, France
1010
           Deepak Rajpal
                                       Sanofi, Paris, France
1011
           Dongyu Liu
                                       Sanofi, Paris, France
1012
1013
1014
           Katherine Call
                                       Sanofi, Paris, France
           Tai-He Xia
                                       Sanofi, Paris, France
           Mitja Kurki
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1015
           Institute, Cambridge, MA, United States
1016
1017
           Samuli Ripatti
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
           Mark Daly
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1017
1018
1019
1020
1021
1022
           Juha Karjalainen
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
           Aki Havulinna
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
           Juha Mehtonen
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
           Priit Palta
           Shabbeer Hassan
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1023
           Pietro Della Briotta Parolo
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1023
1024
1025
1026
1027
1028
1029
           Wei Zhou
                                       Broad Institute, Cambridge, MA, United States
           Mutaamba Maasha
                                       Broad Institute, Cambridge, MA, United States
           Shabbeer Hassan
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
           Susanna Lemmelä
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
                                       University of Stanford, Stanford, CA, United States
           Manuel Rivas
           Aarno Palotie
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1030
           Arto Lehisto
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1031
1032
1033
           Andrea Ganna
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
           Vincent Llorens
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
           Hannele Laivuori
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1034
           Mari E Niemi
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1035
           Taru Tukiainen
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1036
           Mary Pat Reeve
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1037
           Henrike Heyne
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1038
1039
           Nina Mars
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
           Kimmo Palin
                                       University of Helsinki, Helsinki, Finland
1040
           Javier Garcia-Tabuenca
                                       University of Tampere, Tampere, Finland
1041
                                       University of Tampere, Tampere, Finland
           Harri Siirtola
1042
           Tuomo Kiiskinen
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1043
           Jiwoo Lee
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1044
           Institute, Cambridge, MA, United States
1045
           Kristin Tsuo
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1046
           Institute, Cambridge, MA, United States
1047
                                       Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
           Amanda Elliott
1048
           Institute, Cambridge, MA, United States
1049
           Kati Kristiansson
                                       THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1050
           Mikko Arvas
                                       Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
1051
           Helsinki, Finland
1052
           Kati Hyvärinen
                                       Finnish Red Cross Blood Service, Helsinki, Finland
1053
1054
           Jarmo Ritari
                                       Finnish Red Cross Blood Service, Helsinki, Finland
           Miika Koskinen
                                       Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
```

1055

Helsinki

1056 1057	Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
1058	Helsinki Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
1059 1060	District, Oulu, Finland Katri Pylkäs	University of Oulu, Oulu, Finland
1061	Eeva Sliz	University of Oulu, Oulu, Finland
1062	Minna Karjalainen	University of Oulu, Oulu, Finland
1063	Tuomo Mantere	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
1064	District, Oulu, Finland	
1065 1066	Eeva Kangasniemi	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
1067	Tampere, Finland Sami Heikkinen	University of Eastern Finland, Kuopio, Finland
1068	Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
1069	Kuopio, Finland	
1070	Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland
1071		University of Turku, Turku, Finland
1072 1073		akannan University of Turku, Turku, Finland
1073	Nina Pitkänen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland
1075	Biobank directors	
1076	Lila Kallio	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland
1077	Sirpa Soini	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
1078 1079	Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
1079	Helsinki, Finland Eero Punkka	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
1081	Helsinki	Heisinki biobank / Heisinki Oniversity and Hospital District of Heisinki and Ousiniaa,
1082	Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
1083	District, Oulu, Finland	·
1084	Kimmo Savinainen (acting)	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
1085 1086	Tampere, Finland	D' 1 1 CE (E' 1 1/H' ' CE (E' 1 1/M d
1080	Veli-Matti Kosma Kuopio, Finland	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
1088	Teijo Kuopio	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
1089	Jyväskylä, Finland	Contain 1 mand 2100 and 7 cm for only of by taskly at 7 contain 1 mand 110 and 210 and 5
1090		
1091	FinnGen Teams	
1092 1093	Administration	Lating C. M. Landa M. Jaha Phaland Hill IPP Halandar CHaland Platand
1093	Anu Jalanko Huei-Yi Shen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1095	Risto Kajanne	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1096	Mervi Aavikko	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1097		
1098	Analysis	Total Carlot Marie Bill a William Marie Carlot Bill 1/D. 1
1099 1100	Mitja Kurki Institute, Cambridge, MA, U	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1101	Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1102	Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1103	Arto Lehisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1104	Juha Mehtonen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1105	Wei Zhou	Broad Institute, Cambridge, MA, United States
1106 1107	Masahiro Kanai Mutaamba Maasha	Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States
1108	Widdanioa Widasha	broad institute, Cambridge, Mrv, Officed States
1109	Clinical Endpoint Develop	ment
1110	Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1111	Aki Havulinna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1112 1113	Susanna Lemmelä Tuomo Kiiskinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1113	L. Elisa Lahtela	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1115		
1116	Communication	
1117	Mari Kaunisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1118 1119	E-Science	
1119	Elina Kilpeläinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1121	Timo P. Sipilä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1122		Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

1123 1124 1125	Awaisa Ghazal Anastasia Shcherban	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1126	Genotyping					
1127	Kati Donner	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1128	Timo P. Sipilä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1129	Sample Collection Coordination					
1130	Anu Loukola	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,				
1131	Helsinki					
1132						
1133 1134	Sample Logistics					
1134	Päivi Laiho	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1136	Tuuli Sistonen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1137	Essi Kaiharju Markku Laukkanen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1138	Elina Järvensivu	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1139	Sini Lähteenmäki	THE Biobank / The National Institute of Health and Welfare Helsinki, Finland THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1140	Lotta Männikkö	THE Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1141	Regis Wong	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1142	regis wong	THE Broother The Patronal Institute of Floatin and World's Floating, I main				
1143	Registry Data Operations					
1144	Hannele Mattsson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1145	Kati Kristiansson	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1146	Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1147	Sami Koskelainen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1148	Tero Hiekkalinna	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1149	Teemu Paajanen	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland				
1150						
1151	Sequencing Informatics					
1152	Priit Palta	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1153	Kalle Pärn	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1154	Mart Kals	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1155	Shuang Luo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1156	Vishal Sinha	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1157 1158	m • 4					
1156	Trajectory	Didenous Henrich District Terror Pidend				
1160	Tarja Laitinen Mary Pat Reeve	Pirkanmaa Hospital District, Tampere, Finland				
1161	Marianna Niemi	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland University of Tampere, Tampere, Finland				
1162	Harri Siirtola	University of Tampere, Tampere, Finland				
1163	Javier Gracia-Tabuenca	University of Tampere, Tampere, Finland				
1164	Mika Helminen	University of Tampere, Tampere, Finland				
1165	Tiina Luukkaala	University of Tampere, Tampere, Finland				
1166	Iida Vähätalo	University of Tampere, Tampere, Finland				
1167						
1168	Data protection officer					
1169	Tero Jyrhämä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland				
1170		·				
1171	FINBB - Finnish biobank	cooperative				
1172	Marco Hautalahti					
1173	Johanna Mäkelä					
1174	Laura Mustaniemi					
1175	Mirkka Koivusalo					
1176	Sarah Smith					
1177	Tom Southerington					